logo

For the Inventor, By the Inventor

Stevenage, United Kingdom

Colin David Eldred

This inventor holds 17 USPTO granted patents and 1 published patent application and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Glaxo Group Limited, Smithkline Beecham Corporation, Glaxo Wellcome Inc.. Active years: 1988-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Colin David Eldred. Retrieved from https://idiyas.com/inventor/colin-david-eldred

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17 

% Patents Active = 82.4

 

Average Co-Inventor Count = 5.1

ph-index = 7

Forward Citations = 121(Granted Patents)


Location History:

  • Ware, GB (1988 - 1995)
  • Hertford, GB (1999)
  • Herts, GB (1999)
  • Stevenage, GB (2002 - 2012)

Company Filing History:

goldMedal10 out of 1,170 
 
Glaxo Group Limited
 patents
silverMedal5 out of 2,198 
 
Smithkline Beecham Corporation
 patents
bronzeMedal1 out of 281 
 
Glaxo Wellcome Inc.
 patents
4. 1 out of 1,549 
 
Sanofi
 patents

Years Active: 1988-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
Glucocorticoid Receptor Ligands
Morpholinyl-Urea Derivatives
Phosphodiesterase Inhibitors
Inflammatory Diseases
Adenosine Derivatives
Fibrinogen Antagonist
Chemical Compounds
Pyrazole Derivatives
Indole Derivatives
Tetrahydrocarbazolones
Quinoline Derivatives
Piperidineacetic Acid
17 patents (USPTO):Explore Patents
1. 8329730 - Compounds (2012-12-11),
2. 8093281 - Indazoles as glucocorticoid receptor ligands (2012-01-10),
3. 7622464 - Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases (2009-11-24),
4. 7566786 - Quinoline derivatives as phosphodiesterase inhibitors (2009-07-28),
5. 7157457 - Compounds useful in the treatment of inflammatory diseases (2007-01-02),
6. 7101882 - Morpholin-acetamide derivatives for the treatment of inflammatory diseases (2006-09-05),
7. 6740644 - Chemical compounds (2004-05-25),
8. 6677316 - Adenosine derivatives and methods of administration (2004-01-13),
9. 6544960 - Chemical compounds (2003-04-08),
10. 6492348 - Adenosine derivatives (2002-12-10),
11. 6455510 - Chemical Compounds (2002-09-24),
12. 5998388 - Adenosine derivatives (1999-12-07),
13. 5861414 - Piperidineacetic acid derivatives useful as fibrinogen antagonist agent (1999-01-19),
14. 5389659 - C-linked pyrazole derivatives (1995-02-14),
15. 5252593 - Pyrazole containing benzofuran derivatives and pharmaceutical (1993-10-12),

Title: Colin David Eldred: A Pioneer in Pharmaceutical Innovations

Introduction

Colin David Eldred is a distinguished inventor based in Stevenage, GB, known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 17 patents, Eldred has made strides in developing novel compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents, Eldred has focused on compounds that relate to novel oxadiazole derivatives, which exhibit pharmacological activity. These inventions include processes for their preparation, pharmaceutical compositions containing them, and their use in treating various disorders. Additionally, he has worked on indazoles as glucocorticoid receptor ligands, showcasing his innovative approach to drug development.

Career Highlights

Eldred has had a notable career, working with prominent companies such as Glaxo Group Limited and SmithKline Beecham Corporation. His experience in these organizations has allowed him to refine his expertise in pharmaceutical research and development.

Collaborations

Eldred has collaborated with several professionals in his field, including Andrew Michael Kenneth Pennell and Stephen Swanson. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Colin David Eldred's work exemplifies the impact of innovation in the pharmaceutical industry. His contributions through patents and collaborations continue to influence the development of new therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…